While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in cystic fibrosis, cancer and possibly chronic pain.

RNA is a long, polymeric molecule, composed of four different building blocks called nucleotides. In the last decade mRNA has progressed into a promising new class of medicine, with the potential to ...

Nearly 2,000 people have taken part in a groundbreaking trial that aims to help doctors identify more people at risk of ...

AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales. It has several candidates ...

Among the FDA’s pending decisions for this quarter are Vertex’s non-opioid pain drug and Sanofi’s RNA interference therapy ...

Parvinder Singh transformed Ranbaxy into a global pharmaceutical powerhouse, but the empire he built crumbled under his sons’ ...

Investor David Lazar has come to the rescue of cash-strapped Cyclacel Pharmaceuticals, pumping $3 million into the biotech as ...

Roche acquires ADC rights from Innovent for lung cancer treatment in $1 billion deal Roche strengthens its global foothold in ...

John Wood (WG.) has completed the sale of its stake in Ethos Energy Group to One Equity Partners for a net consideration of ...

Korean biotech firms anticipate significant developments in FDA approvals and clinical trials Innovations in medical research ...

Daiichi Sankyo Co. Ltd.’s trophoblast cell surface antigen 2 (Trop2)-directed antibody-drug conjugate (ADC), datopotamab ...

The decision follows a similar one in the US and is due to the drug's failure to significantly improve overall survival versus chemo in the TROPION-Lung01 trial.